Frankfurt - Delayed Quote EUR

CytoMed Therapeutics Limited (F98.F)

2.0000

-0.0400

(-1.96%)

At close: April 30 at 3:29:02 PM GMT+2

CytoMed Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

CytoMed Therapeutics ( NASDAQ:GDTC ) Full Year 2024 Results Key Financial Results Net loss: S$2.52m (loss narrowed by...

Simply Wall St. 23 hours ago

GDTC
CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates

SINGAPORE, April 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived, cell-based allogeneic immunotherapies without engaging in separate activities such as contract manufacturing, contract research, medical device development, or diagnostics, today announced its full-year ended December 31, 2024

GlobeNewswire 2 days ago

GDTC
CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders

SINGAPORE, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”) today released a letter to shareholders from the Chairman of the Company’s Board of Directors (the “Board”) as it welcomes the new year ahead of its full-year audited results announcement due by end-April, the full text of which is provided below. All shareholders of CytoMed are encouraged to read. Dear Shareholders, The Board of CytoMed wishes you a healthy and prosperous Year o

GlobeNewswire 2 months ago

GDTC
Anebulo Pharmaceuticals Leads This Trio Of US Penny Stocks

As the U.S. stock market reacts to tariff news and a wave of earnings reports, major indices like the S&P 500 and Nasdaq Composite are seeing upward movement. For investors considering smaller or newer companies, penny stocks—despite their somewhat outdated name—remain an intriguing investment area with potential value. These stocks can offer unique growth opportunities, especially when backed by strong financials, as we explore several promising candidates in this article.

Simply Wall St. 2 months ago

ANEB

GDTC
CytoMed and SunAct Collaborate on Cancer Immunotherapy Trials in India

The latest announcement is out from CytoMed Therapeutics Limited ( (GDTC) ). CytoMed Therapeutics has entered a collaboration with SunAct Cancer Institute in India to advance the use of its allogeneic gamma delta T cells in a Phase 2 clinical trial aimed at treating solid cancers. This partnership seeks to explore the therapy’s safety and efficacy, potentially providing an affordable treatment option for cancer patients in India, while contributing to global cancer research data. More about Cyto

TipRanks 3 months ago

GDTC
CytoMed Therapeutics and SunAct to conduct solid tumour treatment trial in India

Both entities will jointly sponsor the Phase II clinical trial.

Clinical Trials Arena 3 months ago

GDTC
Sector Update: Health Care Stocks Edge Higher Premarket Monday

Health care stocks were higher in Monday's premarket hours, with the Health Care Select Sector SPDR

PREMIUM
MT Newswires 3 months ago

SPRC

GDTC
CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India

SINGAPORE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic off-the-shelf immunotherapies for the treatment of various cancers, today announced that it has entered into a Business & Research Collaboration Agreement (“BRCA”) with Mumbai-based SunAct Cancer Institute Private Limited

GlobeNewswire 3 months ago

GDTC
CytoMed Therapeutics Leads 3 US Penny Stocks To Consider

As the U.S. equities market begins 2025 on a challenging note, extending its recent slump, investors are keenly observing potential opportunities amid broader market declines. Penny stocks, despite their vintage moniker, continue to attract attention for those interested in smaller or newer companies with potential value. This article explores three penny stocks that stand out for their financial strength and balance sheet resilience, offering intriguing possibilities for investors seeking...

Simply Wall St. 3 months ago

GDTC

HYPR
CytoMed Therapeutics And 2 Other US Penny Stocks To Watch

As the U.S. stock market takes a breather from its record-setting rally, investors are paying close attention to opportunities that may arise in various sectors. Penny stocks, despite their somewhat outdated name, continue to be a focal point for those interested in smaller or newer companies with growth potential. These stocks can offer unique opportunities at lower price points, and when backed by strong financial health and fundamentals, they present an underappreciated chance for growth...

Simply Wall St. 4 months ago

RAVE

IDN

GDTC
Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies

SINGAPORE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Further to an announcement on October 7, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the treatment of blood and solid cancers, is pleased to announce that the first patient has been dosed in its first-in-human Phase I dose-escalation clinical trial (NCT0

GlobeNewswire 5 months ago

GDTC
Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap

As major U.S. indexes recently experienced a downturn, with technology stocks leading the decline and Treasury yields reaching a three-month high, investors are increasingly seeking opportunities beyond the usual large-cap stocks. Penny stocks, while an older term, continue to represent smaller or newer companies that may offer both affordability and growth potential for those willing to explore them. In this article, we examine three penny stocks that stand out for their financial strength...

Simply Wall St. 6 months ago

GDTC

ACRS
CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant

Completion of cash acquisition of licenced cord blood bank expanding CytoMed’s strategy to cord blood-derived biologics through its subsidiary, LongevityBank Pte LtdSINGAPORE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the treatment of various cancers including bloo

GlobeNewswire 6 months ago

GDTC
CytoMed Acquires Cord Blood Assets, Eyes Regenerative Medicine

CytoMed Therapeutics Limited (GDTC) has released an update. CytoMed Therapeutics Limited has expanded its biopharmaceutical focus on cell-based therapies by acquiring a Malaysian cord blood banking license and corresponding assets, including cryopreservation equipment and cord blood units. The move, through its subsidiary LongevityBank, aims to leverage the therapeutic potential of cord blood in regenerative medicine and diseases related to aging. The strategic acquisition signals CytoMed’s inte

TipRanks 6 months ago

GDTC
CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank

SINGAPORE, Oct. 03, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the treatment of various cancers and aging-related diseases, has through its subsidiary, IPSC Depository Sdn Bhd, acquired the licence and certain assets of Cellsafe International Sdn Bhd (In Liquidation), a Malaysia

GlobeNewswire 6 months ago

GDTC
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates

Conference call via Zoom is scheduled for October 8, 2024 at 9 a.m. ET (9 p.m. SGT) https://us06web.zoom.us/meeting/register/tZMrcOmppj0sGdA37lASywTyixRflo9w1TZT SINGAPORE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived, cell-based allogeneic immunotherapies for the treatment of a broad range of cancers including b

GlobeNewswire 6 months ago

GDTC
Presenting on the Emerging Growth Conference 75 Day 2 on September 26

MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 75th Emerging Growth Conference on September 25 & 26, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting

GlobeNewswire 7 months ago

ATWT

SEVCF

UMAC
Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

MIAMI, Aug. 20, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compa

GlobeNewswire 8 months ago

BIDCF

PCYO

SIGY
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now

MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 73rd Emerging Growth Conference on July 17 & 18 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companie

GlobeNewswire 9 months ago

CVKD

GDTC

CRVO
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers

Another Patent Granted for CytoMed's Allogeneic Induced Pluripotent Stem Cell (“iPSC”)-derived Hybrid Gamma Delta Natural Killer T (γδ NKT) cells technologySINGAPORE, July 17, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the treatment of various cancers and aging-related diseases,

GlobeNewswire 9 months ago

GDTC

Performance Overview

Return	F98.F	S&P 500 (^GSPC)
YTD	-24.24%	-5.31%
1-Year	+0.50%	+10.59%
3-Year	-44.90%	+34.78%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

CytoMed Therapeutics Limited (F98.F)

CytoMed Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates

CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders

Anebulo Pharmaceuticals Leads This Trio Of US Penny Stocks

CytoMed and SunAct Collaborate on Cancer Immunotherapy Trials in India

CytoMed Therapeutics and SunAct to conduct solid tumour treatment trial in India

Sector Update: Health Care Stocks Edge Higher Premarket Monday

CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India

CytoMed Therapeutics Leads 3 US Penny Stocks To Consider

CytoMed Therapeutics And 2 Other US Penny Stocks To Watch

Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies

Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap

CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant

CytoMed Acquires Cord Blood Assets, Eyes Regenerative Medicine

CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank

CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates

Presenting on the Emerging Growth Conference 75 Day 2 on September 26

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now

CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers

Performance Overview